Germany - Drugs

Description

The participating health insurance funds pursue the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130c (1) of the German Social Code, Book V for the active ingredient Doravirin. The contract is concluded within the framework of the health insurance funds' open-house original procedure:Individual negotiations on contract content are not conducted; uniform conditions apply. The health insurers do not guarantee exclusivity to individual contract partners. The contract period is a maximum of 24 months beginning on 01.12.2023. The contract ends on 30.11.2025 at the latest, regardless of the date on which the contract was concluded. In case of patent expiration before the above mentioned end date, the contract ends automatically at the end of the month of patent expiration. All further information can be found in the participation and contract documents.
Due to the existence of industrial property rights with regard to the active ingredient or combination of active ingredients that is the subject matter of the contract, the participation and contract documents will only be made available to pharmaceutical companies that offer/market medicinal products containing the active ingredient or combination of active ingredients that is the subject matter of the contract or that can credibly demonstrate to TK that they do so. A contract will be concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration of marketing authorization and company) and confirm this in electronic form pursuant to Section 126a of the German Civil Code (BGB).This announcement does not relate to the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in theSupplement to the Official Journal of the European Union. The designation of the procedure "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. Neither this nor the use of the "TED" medium is in any way connected with submission to procurement law regulations, the application of which is not mandatory by law or procurement regulations.

Opportunity closing date

30 November 2025

Value of contract

to be confirmed